Menu Search
Equities

BIOAGE Labs Inc

Y7G:DUS

BIOAGE Labs Inc

Actions
  • Price (EUR)20.90
  • Today's Change0.10 / 0.48%
  • Shares traded820.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 08 2024 18:40 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. It has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. It is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.

  • Revenue in USD (TTM)0.00
  • Net income in USD-62.16m
  • Incorporated2015
  • Employees58.00
  • Location
    BIOAGE Labs Inc1445A South 50Th StreetRICHMOND 94804United StatesUSA
  • Phone+1 (510) 806-1445
  • Websitehttps://bioagelabs.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.